Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hans Ulrichts

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
The Journal of Laboratory and Clinical Medicine|May 23, 2003
Integrin alphaIIbbeta3 and shear-dependent action of glycoprotein Ibalpha stimulate platelet-dependent thrombin formation in stirred plasmaJeffrey F W Keuren, Hans Ulrichts, Marion A H Feijge, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|April 23, 2005
Synergistic effect of thrombin on collagen-induced platelet procoagulant activity is mediated through protease-activated receptor-1Jeffrey F W Keuren, Simone J H Wielders, Hans Ulrichts, et al.
Blood|September 6, 2012
Evaluation of efficacy and safety of the anti-VWF Nanobody ALX-0681 in a preclinical baboon model of acquired thrombotic thrombocytopenic purpuraFilip Callewaert, Jan Roodt, Hans Ulrichts, et al.
Bioanalysis|August 1, 2023
A biomarker assay validation approach tailored to the context of use and bioanalytical platformElizabeth S Hickford, Lien Dejager, Daisy Yuill, et al.
Arthritis Research & Therapy|May 22, 2015
The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritisMaarten Van Roy, Cedric Ververken, Els Beirnaert, et al.
The American Journal of Cardiology|January 28, 2010
Relation of endothelial function to residual platelet reactivity after clopidogrel in patients with stable angina pectoris undergoing percutaneous coronary interventionOlivier Muller, Michalis Hamilos, Jozef Bartunek, et al.
Blood|May 18, 2011
Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugsHans Ulrichts, Karen Silence, Anne Schoolmeester, et al.
The New England Journal of Medicine|February 11, 2016
Caplacizumab for Acquired Thrombotic Thrombocytopenic PurpuraFlora Peyvandi, Marie Scully, Johanna A Kremer Hovinga, et al.
Thrombosis and Haemostasis|June 10, 2011
The in vitro effect of the new antithrombotic drug candidate ALX-0081 on blood samples of patients undergoing percutaneous coronary interventionJanine E van Loon, Peter P T de Jaegere, Hans Ulrichts, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 10, 2010
CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cellsSven Jähnichen, Christophe Blanchetot, David Maussang, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
The Journal of Laboratory and Clinical Medicine|May 23, 2003
Integrin alphaIIbbeta3 and shear-dependent action of glycoprotein Ibalpha stimulate platelet-dependent thrombin formation in stirred plasmaJeffrey F W Keuren, Hans Ulrichts, Marion A H Feijge, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|April 23, 2005
Synergistic effect of thrombin on collagen-induced platelet procoagulant activity is mediated through protease-activated receptor-1Jeffrey F W Keuren, Simone J H Wielders, Hans Ulrichts, et al.
Blood|September 6, 2012
Evaluation of efficacy and safety of the anti-VWF Nanobody ALX-0681 in a preclinical baboon model of acquired thrombotic thrombocytopenic purpuraFilip Callewaert, Jan Roodt, Hans Ulrichts, et al.
Bioanalysis|August 1, 2023
A biomarker assay validation approach tailored to the context of use and bioanalytical platformElizabeth S Hickford, Lien Dejager, Daisy Yuill, et al.
Arthritis Research & Therapy|May 22, 2015
The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritisMaarten Van Roy, Cedric Ververken, Els Beirnaert, et al.
The American Journal of Cardiology|January 28, 2010
Relation of endothelial function to residual platelet reactivity after clopidogrel in patients with stable angina pectoris undergoing percutaneous coronary interventionOlivier Muller, Michalis Hamilos, Jozef Bartunek, et al.
Blood|May 18, 2011
Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugsHans Ulrichts, Karen Silence, Anne Schoolmeester, et al.
The New England Journal of Medicine|February 11, 2016
Caplacizumab for Acquired Thrombotic Thrombocytopenic PurpuraFlora Peyvandi, Marie Scully, Johanna A Kremer Hovinga, et al.
Thrombosis and Haemostasis|June 10, 2011
The in vitro effect of the new antithrombotic drug candidate ALX-0081 on blood samples of patients undergoing percutaneous coronary interventionJanine E van Loon, Peter P T de Jaegere, Hans Ulrichts, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 10, 2010
CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cellsSven Jähnichen, Christophe Blanchetot, David Maussang, et al.
Pageof 2